Preventing Growth Restriction & Preterm Birth in High-Infectious Countries
Join experts Dr. Matthew Chico and Prof. Asma Khalil in researching interventions to prevent growth restriction and preterm birth in countries with high infectious disease burdens. Explore the impact of clinical trials in East and Southern Africa, focusing on improving maternal and child health outcomes. Learn more about the IMPROVE and ASPIRE trials and their significance in advancing prenatal care in resource-limited settings.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Preventing growth restriction and preterm birth in countries with a high infectious disease burden Dr Matthew Chico (LSHTM) and Prof Asma Khalil (SGUL) Email: matthew.chico@lshtm.ac.uk Email: akhalil@sgul.ac.uk
Prof Asma Khalil Background Expert in fetal medicine, multiple (twin) pregnancy, prenatal screening, prenatal diagnosis, chorionic villus sampling, amniocentesis, obstetric ultrasound, Doppler assessment, fetal growth restriction, pre- eclampsia (hypertension in pregnancy), fetal therapy, laser treatment of twin-twin transfusion syndrome. Research focus includes mixed methods, epidemiology, clinical trials, systematic reviews, and mixed methods process evaluation Email: akhalil@sgul.ac.uk
Dr Matthew Chico Background Expert in design and conduct of impact evaluations and clinical trials aimed at improving maternal, reproductive, newborn and child health in low- and middle-income countries. Research focus is on expanding packages of care as supported by local epidemiology and operational capacity to address co-morbidities and reduce social inequities through the lifecycle. Email: matthew.chico@lshtm.ac.uk
Research context The successful MRC LID applicant will join a multidisciplinary team involved in understanding the underlying mechanisms that contribute to adverse pregnancy outcomes and interventions that may help to overcome them. Doctoral training will involve the use of clinical data and biological samples already collected from two large randomised controlled trials (RCTs) recently completed in East and Southern Africa.
Research context More information about these trials can be found on ClinicalTrials.gov IMPROVE trial: Kenya, Tanzania, and Malawi (N=4,680) https://clinicaltrials.gov/study/NCT03208179 ASPIRE trial: Zambia (N=5,436) https://clinicaltrials.gov/study/NCT04189744 These RCTs involved the monthly administration of intermittent preventive treatment in pregnancy (IPTp) during the second and third trimesters.
Research context IMPROVE and ASPIRE compared the standard of care IPTp recommended by the World Health Organization (WHO) with sulfadoxine pyrimethamine (SP) against alternative regimens chosen for their potential to provide superior protection against malaria and curable sexually transmitted and reproductive tract infections (STIs/RTIs) in pregnancy.
Research context At this juncture, we have clinical data (antenatal care provided during pregnancy and pregnancy outcomes) and samples bio-banked to investigate the vaginal and intestinal microbiomes of participants. This will involve case-control studies of normal versus adverse pregnancy outcomes. This research will inform current IPTp policy and the future research agenda that stand to impact over 50 million pregnant women at risk of malaria and/or curable STIs/RTIs in sub-Saharan Africa.
Research Partners In addition to being supported by SGUL and LSHTM, the successful MRC LID applicant will also work closely with and as needed in the facilities of UK partners who have been involved in the IMPROVE and ASPIRE trials, expanding his/her professional network. UK partners to include University College London, Imperial College London and Liverpool School of Tropical Medicine African partners include National Institute of Medical Research (Tanzania) and the Tropical Disease Research Centre (Zambia)
